Featured Research

from universities, journals, and other organizations

Molecular disease model for melanoma

Date:
March 30, 2011
Source:
Public Library of Science
Summary:
A new molecular disease model of melanoma classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

Cancer Commons, an initiative of CollabRx, a provider of information technology to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model of melanoma (MDMM) which classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

Published as a "dynamic" review paper by a panel of leading researchers and clinicians affiliated with the Cancer Commons initiative, the MDMM is maintained online, curated by the authors and continuously updated based on input from the melanoma community to reflect the latest scientific, clinical and technological advancements in cancer research and treatment. The MDMM is designed as an interface between the research and clinical communities where researchers can learn from clinical outcomes to refine molecular subtypes and clinicians can use the latest subtype information in treatment decisions. In this way, the online melanoma disease model becomes the core of an adaptive, rapid learning community that provides each patient with the best possible outcome while aggregating results over all patients to advance the standard of care.

The MDMM consists of a set of "actionable" molecular subtypes and proposed practice guidelines for treating each subtype: which therapies (approved or experimental) should be considered and which are contraindicated. A molecular subtype of melanoma is loosely defined as those tumors containing the same set of molecular (primarily genetic) defect(s) and their associated pathways. A subtype is deemed actionable if there is both a CLIA-approved assay to determine whether a given tumor fits that classification, and at least one FDA-approved or experimental targeted therapy with potential efficacy for that subtype.

Commented Dr. Keith Flaherty, Director of Developmental Therapeutics at Massachusetts General Hospital and co-chief editor of Cancer Commons Melanoma: "While earlier stages of melanoma can be successfully treated by surgical excision, advanced stages are uniquely refractory to standard chemotherapy. Recent developments in our understanding of the molecular drivers of this disease have led to a new generation of targeted therapies that are proving effective in patients whose tumors harbor certain genetic defects. Rather than treating melanoma as a single disease, it makes sense to stratify tumors into molecular subtypes and treat each with the most appropriate therapies."

The molecular disease model for melanoma is the first of many such models planned by Cancer Commons, the open science initiative for personalized oncology that was initially convened by CollabRx. Cancer Commons is creating a network of rapid learning communities where physicians, scientists, and patients collaborate to provide each patient with the best possible outcome by personalizing therapy based on the tumor's genomic subtype. CollabRx is developing web-based applications and services that facilitate this collaboration; the first of these, The Targeted Therapy Finder -- Melanoma, leverages the MDMM to find treatments targeted to a patient's specific molecular profile.

Funding: SJV, JMT, MDT and JS are or were employees of CollabRx, Inc. a for-profit corporation. They played intimate roles in the research and preparation of the manuscript.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Smruti J. Vidwans, Keith T. Flaherty, David E. Fisher, Jay M. Tenenbaum, Michael D. Travers, Jeff Shrager. A Melanoma Molecular Disease Model. PLoS ONE, 2011; 6 (3): e18257 DOI: 10.1371/journal.pone.0018257

Cite This Page:

Public Library of Science. "Molecular disease model for melanoma." ScienceDaily. ScienceDaily, 30 March 2011. <www.sciencedaily.com/releases/2011/03/110330192214.htm>.
Public Library of Science. (2011, March 30). Molecular disease model for melanoma. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2011/03/110330192214.htm
Public Library of Science. "Molecular disease model for melanoma." ScienceDaily. www.sciencedaily.com/releases/2011/03/110330192214.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins